Comparing biomarkers as trial level general surrogates.

ABSTRACT: An intermediate response measure that accurately predicts efficacy in a new setting can reduce trial cost and time to product licensure. In this article, we define a trial level general surrogate, which is an intermediate response that can be used to accurately predict efficacy in a new setting. Methods for evaluating general surrogates have been developed previously. Many methods in the literature use trial level intermediate responses for prediction. However, all existing methods focus on surrogate evaluation and prediction in new settings, rather than comparison of candidate general surrogates, and few formalize the use of cross validation to quantify the expected prediction error. Our proposed method uses Bayesian non-parametric modeling and cross-validation to estimate the absolute pr

SUBMITTER: Gabriel EE 

PROVIDER: S-EPMC5045774 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature